NYSE:NHWK NightHawk Biosciences (NHWK) Stock Price, News & Analysis → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Free NHWK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.26▼$0.5052-Week Range N/AVolume173,100 shsAverage Volume97,242 shsMarket Capitalization$10.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesSocial MediaStock AnalysisEarningsHeadlinesInsider TradesSocial Media Get NightHawk Biosciences alerts: Email Address Ad Chaikin Analytics“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.Just click here. About NightHawk Biosciences Stock (NYSE:NHWK)NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.Read More Ad Chaikin Analytics“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.Just click here. NHWK Stock News HeadlinesMarch 19, 2024 | globenewswire.comScorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major UniversityMarch 14, 2024 | globenewswire.comScorpius Holdings Accepted as a Member of the US Government's BioMaP-ConsortiumApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 12, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Closing of Public OfferingMarch 8, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Pricing of Public OfferingMarch 7, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Proposed Public Offering of Common StockMarch 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023March 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 13, 2024 | uk.finance.yahoo.comScorpius Holdings, Inc. (SCPX)February 7, 2024 | msn.comNightHawk Biosciences Debuts SCPX Ticker on NYSE AmericanFebruary 7, 2024 | msn.comNightHawk Biosciences Unveils New Name and TickerJanuary 31, 2024 | msn.comNightHawk Biosciences Strikes Key Licensing and Financing DealsJanuary 30, 2024 | finance.yahoo.comNightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing NoteJanuary 25, 2024 | finance.yahoo.comNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical ProgramJanuary 17, 2024 | finanznachrichten.deNightHawk Biosciences: NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientJanuary 16, 2024 | finance.yahoo.comNightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientJanuary 11, 2024 | msn.comNHWK: Transformational ChangesJanuary 8, 2024 | msn.comNightHawk Biosciences changing name to Scorpius, ticker to SCPXJanuary 8, 2024 | finance.yahoo.comNightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMOJanuary 3, 2024 | finance.yahoo.comNightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National UniversityDecember 21, 2023 | finance.yahoo.comNightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research UniversityDecember 19, 2023 | msn.comNightHawk Biosciences files for $200M mixed securities shelfDecember 18, 2023 | finance.yahoo.comNightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical CompanyDecember 12, 2023 | finance.yahoo.comNightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core AssetsDecember 3, 2023 | morningstar.comNightHawk Biosciences Inc NHWKNovember 29, 2023 | bizjournals.comMorrisville public company looks to divest subsidiary after CEO tried to buy itSee More Headlines Receive NHWK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NHWK CUSIPN/A CIK1476963 Webwww.nighthawkbio.com Phone919-240-7133FaxN/AEmployees77Year Founded2008Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,440,000.00 Net Margins-2,333.27% Pretax Margin-2,546.97% Return on Equity-91.62% Return on Assets-56.48% Debt Debt-to-Equity Ratio0.27 Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$6.38 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.82 per share Price / BookN/AMiscellaneous Outstanding Shares26,080,000Free Float21,935,000Market Cap$10.78 million OptionableOptionable Beta0.19 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jeffrey Alan Wolf J.D. (Age 61)Founder, Chairman of the Board, CEO & President Comp: $842.6kMr. William L. Ostrander (Age 56)CFO & Secretary Comp: $476.24kDr. Justin Stebbing FRCPFRCPath, M.A., M.D., Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardColonel George E. Peoples Jr.F.A.C.S., M.D., Chief Medical AdvisorMs. Ania SzymanskaHead of QualityKey CompetitorsEterna TherapeuticsNASDAQ:ERNAGalera TherapeuticsNASDAQ:GRTXGuardion Health SciencesNASDAQ:GHSIMoleculin BiotechNASDAQ:MBRXMonopar TherapeuticsNASDAQ:MNPRView All Competitors NHWK Stock Analysis - Frequently Asked Questions How were NightHawk Biosciences' earnings last quarter? NightHawk Biosciences, Inc. (NYSE:NHWK) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.01. The biopharmaceutical company earned $0.50 million during the quarter, compared to analysts' expectations of $0.57 million. NightHawk Biosciences had a negative trailing twelve-month return on equity of 91.62% and a negative net margin of 2,333.27%. When did NightHawk Biosciences' stock split? NightHawk Biosciences shares reverse split on the morning of Friday, December 11th 2020. The 1-7 reverse split was announced on Thursday, December 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. This page (NYSE:NHWK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWill this $2 AI stock double overnight?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NightHawk Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
